Background
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide fragment derived from human gastric juice protein. It has been studied extensively in animal models for its regenerative and cytoprotective effects across multiple tissue types including gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue.
This comprehensive review by Sikiric et al. — the primary research group behind BPC-157 — synthesizes decades of preclinical work and provides the most thorough mechanistic overview available.
Methods
Narrative review and meta-analysis of preclinical BPC-157 studies (rodent models predominantly). Encompassed studies of GI healing, musculoskeletal repair, anti-inflammatory effects, and NO-system involvement.
Key Findings
Gastrointestinal effects:
- Accelerated healing of esophageal, gastric, and colonic ulcerations in rat models
- Protected against NSAID-induced GI lesions (both preventive and therapeutic administration)
- Reversed alcohol-induced gastric ulceration within 24–48 hours in rat models
- No toxicity observed up to 1,000 μg/kg in acute and sub-chronic dosing
Musculoskeletal effects:
- Transected Achilles tendons: significantly faster tendon-to-bone reattachment
- Crush injuries: reduced inflammatory phase, earlier collagen organization
- Bone healing: accelerated osteogenesis in fracture models
- Ligament healing: reduced scarring, maintained biomechanical strength
Mechanistic pathways:
- Nitric oxide (NO) system modulation
- Upregulation of growth factor receptors (VEGFR2, FGFR2)
- Anti-inflammatory via NF-κB inhibition
- Maintained gut microbiome diversity under stress
Clinical Significance
While BPC-157 lacks human RCT data, the breadth and consistency of its preclinical evidence across multiple tissue types and injury models is notable. The peptide’s GI origin and oral/topical bioavailability in animal studies have generated significant interest for gut health and orthopedic recovery applications.
The safety profile across animal studies (no known LD50, no mutagenicity) supports cautious human exploration, and anecdotal clinical reports are accumulating — though not yet systematized.
Limitations
- All mechanistic data from animal models; no published human RCTs
- Single primary research group (Sikiric et al.) produces the majority of BPC-157 literature
- Dose translation from animal to human unclear
- Regulatory status: not FDA approved; sold as research peptide only